Cover Image

Renal microangiopathy induced by lenvatinib in hepatocellular carcinoma: a case report and literature review

Lenvatinib, a multi-target inhibitor of receptor tyrosine kinases, has been increasingly used in the treatment of advanced hepatocellular carcinoma (HCC). However, its association with renal adverse effects, including proteinuria and renal microvascular complications, was not fully understood in HCC...

Full description

Saved in:

Bibliographic Details
Main Authors:	Cheng Xue (Author), Linlin Cui (Author), Jiaxin Chen (Author), Yang Liu (Author), Yufei Deng (Author), Wenyi Xu (Author), Zhiguo Mao (Author), Jun Wu (Author)
Format:	Book
Published:	Frontiers Media S.A., 2024-11-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Lenvatinib for Hepatocellular Carcinoma: A Literature Review
by: Takeshi Hatanaka, et al.
Published: (2021)

The role of lenvatinib in the era of immunotherapy of hepatocellular carcinoma
by: Matthew Man Pok Lee, et al.
Published: (2023)

Clinical study of lenvatinib in the treatment of hepatitis virus-related hepatocellular carcinoma and antiviral therapy
by: Xiaomi Li, et al.
Published: (2023)

Impact of genetic polymorphisms on the pharmacokinetics and pharmacodynamics of lenvatinib in patients with hepatocellular carcinoma
by: Hironao Okubo, et al.
Published: (2022)

A bibliometric study on the utilization of lenvatinib in hepatocellular carcinoma (2014-2022)
by: Cong-Cong Wang, et al.
Published: (2023)

Lenvatinib Plus PD-1 Inhibitors versus Regorafenib in Patients with Advanced Hepatocellular Carcinoma After the Failure of Sorafenib: A Retrospective Study
by: Xu Y, et al.
Published: (2023)

Lenvatinib-induced severe generalized erythematous rash in a patient with hepatocellular carcinoma
by: Yukari Matsumoto, et al.
Published: (2022)

Lenvatinib-induced psoriasiform eruption and palmoplantar erythema in a patient with hepatocellular carcinoma
by: Rachel Sally, BA, et al.
Published: (2021)

The evolving role of lenvatinib at the new era of first-line hepatocellular carcinoma treatment
by: Landon L. Chan, et al.
Published: (2024)

Comparison of atezolizumab plus bevacizumab and lenvatinib for hepatocellular carcinoma with portal vein tumor thrombosis
by: Jeayeon Park, et al.
Published: (2024)

circRNA circMED27 acts as a prognostic factor and mediator to promote lenvatinib resistance of hepatocellular carcinoma
by: Pengfei Zhang, et al.
Published: (2022)

Risk Factors for Hepatic Encephalopathy in Hepatocellular Carcinoma After Sorafenib or Lenvatinib Treatment: A Real-World Study
by: Chen B, et al.
Published: (2022)

Cost-effectiveness analysis of transarterial chemoembolization combined with lenvatinib as the first-line treatment for advanced hepatocellular carcinoma
by: Ying He, et al.
Published: (2023)

Comprehensive Treatment of Trans-Arterial Chemoembolization Plus Lenvatinib Followed by Camrelizumab for Advanced Hepatocellular Carcinoma Patients
by: Juanfang Liu, et al.
Published: (2021)

Clinical use of lenvatinib in combination with everolimus for the treatment of advanced renal cell carcinoma
by: Leonetti A, et al.
Published: (2017)

Organ specific responses to first-line lenvatinib plus anti-PD-1 antibodies in patients with unresectable hepatocellular carcinoma: a retrospective analysis
by: Cheng Huang, et al.
Published: (2021)

Histopathological features of thrombotic microangiopathies in renal biopsies
by: Miguel Ernandes Neto, et al.
Published: (2019)

Renal thrombotic microangiopathy in an ANCA-associated vasculitis
by: Ana Teresa Domingos, et al.
Published: (2019)

Identification of Fasudil as a collaborator to promote the anti-tumor effect of lenvatinib in hepatocellular carcinoma by inhibiting GLI2-mediated hedgehog signaling pathway
by: Yilan Huang, et al.
Published: (2024)

Cost-effectiveness analysis of sintilimab plus bevacizumab biosimilar compared with lenvatinib as the first-line treatment of unresectable or metastatic hepatocellular carcinoma
by: Ting Zhou, et al.
Published: (2022)

Safety and Effectiveness of Lenvatinib in Patients with Unresectable Hepatocellular Carcinoma in Real-World Clinical Practice: An Observational Post-Marketing Study in Japan
by: Junji Furuse, et al.
Published: (2023)

Radiotherapy plus lenvatinib versus radiotherapy plus sorafenib for hepatocellular carcinoma with portal vein tumor thrombus: a retrospective study
by: Min Zhang, et al.
Published: (2024)

Impact of Adverse Events on the Progression-Free Survival of Patients with Advanced Hepatocellular Carcinoma Treated with Lenvatinib: A Multicenter Retrospective Study
by: Takamasa Ohki, et al.
Published: (2020)

Microangiopathy
Published: (2012)

Efficacy of lenvatinib combined with sequential transarterial chemoembolization for primary hepatocellular carcinoma and the effects on serum basic fibroblast growth factor and vascular endothelial growth factor
by: Qing-Yun Xie, et al.
Published: (2022)

Pembrolizumab and lenvatinib in recurrent ovarian clear cell carcinoma resistant to chemotherapy
by: Blair McNamara, et al.
Published: (2023)

Clinico-Histological Features of Thrombotic Microangiopathy in Renal Biopsies: A Retrospective Study
by: Niraimathi MANICKAM, et al.
Published: (2022)

Effects of three flavonoids on the metabolism of lenvatinib
by: Jinzhao Yang, et al.
Published: (2024)

Case report: Remarkable response to sintilimab, lenvatinib, and nab-paclitaxel in postoperative metastatic chemotherapy-resistant combined hepatocellular-cholangiocarcinoma
by: Nan Zhou, et al.
Published: (2023)

Renal thrombotic microangiopathy caused by interferon beta-1a treatment for multiple sclerosis
by: Mahe J, et al.
Published: (2013)

How the National Health Insurance Coverage policy changed the use of lenvatinib for adult patients with advanced hepatocellular carcinoma: a retrospective cohort analysis with real world big data
by: Yanyan Liu, et al.
Published: (2023)

COVID-19 and thrombotic microangiopathy
by: E. V. Sluhanchuk, et al.
Published: (2022)

Transplant-associated thrombotic microangiopathy
by: Tomasz Jarmoliński
Published: (2021)

Differences in the pharmacokinetics and steady-state blood concentrations of orally administered lenvatinib in adult and juvenile rats
by: Xiaoyue Du, et al.
Published: (2023)

Malignant hypertension as a rare cause of thrombotic microangiopathy associated with end-stage renal disease
by: J. C. Charles, et al.
Published: (2024)

Immunotherapies for advanced hepatocellular carcinoma
by: Li-Yang Sun, et al.
Published: (2023)

Combination lenvatinib plus pembrolizumab in the treatment of ovarian clear cell carcinoma: A case series
by: Corinne A. Calo, et al.
Published: (2023)

Influence of Lenvatinib on the Functional Reprogramming of Peripheral Myeloid Cells in the Context of Non-Medullary Thyroid Carcinoma
by: Chunying Peng, et al.
Published: (2023)

THROMBOTIC MICROANGIOPATHY IN THE PATHOGENESIS OF OBSTETRIC COMPLICATIONS
by: S. V. Akinshina, et al.
Published: (2016)

Angiotensin Blockade Beyond Hypertension in Autosomal Dominant Polycystic Kidney Disease
by: Shuqin Mei, et al.
Published: (2024)